ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Dec 18, 2020 13:09 JST
Source:
Eisai
Eisai Completes Construction of the 5th Manufacturing Building at Kawashima Industrial Park in Japan
To Strengthen Its in-House Production Function for Formulating Anti-Cancer Agent Lenvima?
TOKYO, Dec 18, 2020 - (JCN Newswire) - Eisai Co., Ltd. announced that it has completed construction of the 5th manufacturing building at the Kawashima Industrial Park located in Gifu Prefecture, Japan.
External views of the 5th manufacturing building
The 5th manufacturing building is a facility specifically designated for formulating anti-cancer drugs (total floor area: approximately 4,500m2). Since anti-cancer drugs are highly active, this building is designed to make it possible to manufacture anti-cancer agents more safely, with various preventive features for controlling highly active substances, such as preventing cross-contamination of agents and exposure to workers. Eisai plans to manufacture its in-house discovered and developed anti-cancer agent Lenvima, which are in increasing demand worldwide, at this facility from FY2021. We also secure space for further installation of manufacturing equipment for other anti-cancer drugs within this building. The total investment for the construction of the 5th manufacturing building is approximately 5 billion yen.
The Kawashima Industrial Park, opened in 1966, is Eisai?s global pharmaceutical manufacturing base. In addition, this Industrial Park is a role model factory for our global production activities, where we are making new progresses such as utilizing digital technology and new technologies. With the completion of the 5th manufacturing building, Eisai will further expand the stable supply system of high-quality pharmaceuticals in Japan, and continues further contribution to improve the benefits of patients and their families in Japan and around the world.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
MHI Thermal Systems Air-Conditioners for the Australian Market Recognized with Prestigious Awards
Oct 17, 2025 23:37 JST
SEKISUI CHEMICAL, Fujitsu, and SAP Japan announce comprehensive modernization of management platform to drive data-driven approach
Oct 17, 2025 23:00 JST
TransNusa to Launch Bali - Singapore Scheduled Flight on November 17
Oct 17, 2025 16:58 JST
MHIEC Receives Contract for Improvement of Core Equipment at Municipal Solid Waste Incineration Facility in Kanazawa
Oct 16, 2025 23:57 JST
Overview of Honda Exhibits at Japan Mobility Show 2025
Oct 16, 2025 23:20 JST
DENSO to Exhibit at JAPAN MOBILITY SHOW 2025
Oct 16, 2025 22:53 JST
Fujitsu and IISc launch joint research on advanced AI technologies to accelerate new material development and resolve societal challenges
Oct 16, 2025 21:55 JST
Mitsubishi Motors Wins Triple Honors at Good Design Award 2025 in Japan with the Delica Mini, Destinator and Delica Series
Oct 15, 2025 21:29 JST
Mitsubishi Motors at Japan Mobility Show 2025: World Premiere of Electrified Crossover SUV Concept
Oct 15, 2025 20:35 JST
Honda to Present World Premiere of ProZision(TM) Autonomous, at Equip Exposition 2025, Honda Battery-powered Autonomous Riding Lawn Mower
Oct 15, 2025 19:56 JST
Honda to Make Additional Investment in U.S.-based Helm.ai to Further Enhance Development of Next-generation AD/ADAS
Oct 15, 2025 19:25 JST
MHI Thermal Systems Wins 2025 GOOD DESIGN AWARD for Hyper Multi LXZ Series of Building-Use Multi-Split Air-Conditioners in Japan
Oct 15, 2025 18:50 JST
Mitsubishi Power Marks 60 Years in Saudi Arabia with Unveiling of First Locally Assembled JAC Gas Turbine at Dammam Assembly Facility
Oct 14, 2025 18:21 JST
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
Oct 14, 2025 17:54 JST
Mazda Announces Exhibition at JAPAN MOBILITY SHOW 2025
Oct 14, 2025 17:38 JST
Hitachi Advances Strategic Alliance with Google Cloud to Empower Frontline Workers with Field-Specific AI Agents
Oct 11, 2025 00:58 JST
Honda Issues Integrated Report - "Honda Report 2025"
Oct 11, 2025 00:46 JST
DENSO's Electrification Products Adopted for TOYOTA's New "bZ4X"
Oct 11, 2025 00:21 JST
Newly developed eAxle adopted for TOYOTA's new "bZ4X"
Oct 11, 2025 00:08 JST
MHIET and MHI-TC Complete Delivery of First "COORDY" Controller Providing Optimized Control of Multiple Power Sources
Oct 10, 2025 23:47 JST
More Latest Release >>
Related Release
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
10/14/2025 5:54:00 PM JST
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
10/8/2025 12:03:00 PM JST
Eisai Highlights Breadth of Oncology Research at ESMO 2025
10/3/2025 6:01:00 PM JST
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
9/29/2025 10:33:00 AM JST
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
9/24/2025 7:04:00 PM JST
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
9/17/2025 6:20:00 PM JST
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
9/12/2025 1:20:00 PM JST
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
9/8/2025 5:49:00 PM JST
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025
9/4/2025 10:56:00 AM JST
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
9/3/2025 11:32:00 AM JST
More Press release >>